Navigation Links
RU-486, The Abortion Pill, May Quell The Breast Cancer Gene

The abortion drug RU-486 was used by scientists in mice that were bred with a breast cancer gene. The drug turned beneficial in warding off potential tumors.//

This is thought to have been possible due to the abortion drug, known to inhibit the hormone, progesterone. This is indeed a teaser to researchers to evolve a safe version of the hormone blocker as an option for women carrying the breast cancer gene.

Cell biologist Eva Lee of the University of California, Irvine, who led the research said, 'All of us have to be cautious. But I do think if there is a better anti-progesterone available, hopefully there will be other options in the future for these women.'

This has certainly raised the curiosity of the scientists who could translate the success in the mouse model and reflect it on better drugs for humans. Once scientists are able to nail how BRCA1 actually causes tumors, it will enable the knowledge to tide over the bad effects of BRCA1.

As part of the research, Lee and colleagues nurtured mice whose mammary glands accommodated only the BRCA1 mutation. Scientists actually found that the bad gene, which caused breast cancers, was also responsible in the breast tissue portraying high levels of progesterone receptors. The final proof came from RU-486, also known as mifepristone. It triggers human abortions by inhibiting progesterone, a hormone that is extremely important to support pregnancy.

In the experiment, Lee implanted a pellet of RU -486 in some of the cancer-susceptible mice; the drug would gradually be released into their bodies, over a period of two months. The finding revealed that within 8 months of age, the mice that were not treated, developed tumors. But the mice which were given RU-486 had not developed tumors at the end of the year. But researchers left a warning, that prolonged use of RU-486 is not recommended. Other varieties of progesterone-blockers which are safe for prolonged use are in the process of being developed.
SAV
'"/>




Related medicine news :

1. Abortion Pill approved by FDA
2. Abortion made easy pill causes alarm in state
3. Treatment for fibroids with "Abortion Pill"
4. Abortion may cause mental illness
5. Abortion Does Not Increase Risk Of Depression In Women
6. Teenage Girls May Not Need Parents Consent For Abortion
7. Botched Abortions Trigger Concern Over Legal Ambiguity In Britain
8. Mystery Surrounding Use Of Abortion Pill Yet To Be Resolved
9. Mother Claims Hefty Compensation For Failed Abortion Of Twins
10. Abortions does not increase risk of breast cancer
11. Bill to Ban Abortion In Indiana Introduced
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 ... ... the Workers Compensation Research Institute (WCRI) officially opened registration today for its ... Place Hotel in Boston, MA . , The theme of the conference is ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology: